Novel Approaches Towards Treating Advanced Liver Diseases and Fibrosis

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from University Strasburg / INSERM.

The portfolio is based on deep competence in liver diseases and fibrosis and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which showed consistent compelling efficacy in multiple animal models of fibrosis and liver cancer.

Alentis further has a proprietary discovery platform that allows for efficient discovery of compounds and targets that are relevant in the pathology of late stage liver diseases.

NOVEL APPROACHES TOWARDS TREATING ADVANCED LIVER DISEASES AND FIBROSIS​

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from University Strasburg / INSERM.

The portfolio is based on deep competence in liver diseases and fibrosis and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which showed consistent compelling efficacy in multiple animal models of fibrosis and liver cancer.

Alentis further has a proprietary discovery platform that allows for efficient discovery of compounds and targets that are relevant in the pathology of late stage liver diseases.